Organigram Global Inc Reports Record Revenue and Expands Internationally Amid Challenges

Organigram Global Inc reported record Q3 revenue, driven by strong domestic market leadership and international expansion. However, the integration of Motif caused temporary disruptions and adjusted gross margin rate decreased. Net loss was $6.3 million, and operating expenses increased 8.5%. The company awaits EU GMP certification and expects margin improvements in Q4 and 2026.

Title: Organigram Global Inc Reports Record Q3 Revenue Amid Integration Challenges

Organigram Global Inc. (NASDAQ: OGI; TSX: OGI), Canada's leading cannabis company, announced record third-quarter (Q3) fiscal 2025 results, driven by strong domestic market leadership and international expansion. The company reported gross revenue of $110.2 million, a 73% increase year-over-year, and net revenue of $70.8 million, up 72% year-over-year [1].

The company's adjusted EBITDA grew by 64% to $5.7 million, while free cash flow improved to $5.0 million from ($4.8) million in the prior year. International sales contributed significantly to the company's growth, with international revenue reaching $7.4 million, up 208% year-over-year [1].

However, the integration of Motif Labs Ltd. (Motif) caused temporary disruptions, leading to a decrease in adjusted gross margin from 36% in Q3 2024 to 34% in Q3 2025. The company's net loss increased to $6.3 million from a net income of $2.8 million in Q3 2024, primarily due to higher fair value changes recognized in relation to preferred shares and other financial instruments [1].

Operating expenses increased by 70% to $24.5 million, driven by the inclusion of Motif's SG&A expenses and higher trade investments. The company expects to realize cost synergies related to the Motif acquisition, which could positively impact future earnings and improve adjusted gross margin in the coming quarters [1].

Organigram continues to expand its international presence, awaiting EU-GMP certification for its Moncton facility. The company also began generating U.S. recreational revenue from hemp-derived THC beverages pursuant to the acquisition of Collective Project, expanding its distribution into new states and gaining key account listings [1].

As of June 30, 2025, the company had total cash of $85.9 million, including $35.9 million of unrestricted cash and negligible debt. The company's balance sheet shows a strong liquidity position, with total assets of $564.6 million and total liabilities of $179.1 million [1].

Looking ahead, Organigram expects to continue growing its international sales and achieve margin improvements in Q4 2025 and 2026. The company's CEO, Beena Goldenberg, stated, "We are committed to bringing our Canadian successes to international markets and becoming a truly global cannabis player" [1].

References:
[1] https://www.businesswire.com/news/home/20250813807480/en/Organigram-Reports-Record-Third-Quarter-Fiscal-2025-Results